Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a primary cancer of the uterine lining (endometrial carcinoma), including specific types such as endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma
- People whose initial surgery included removal of the uterus (hysterectomy), both ovaries and fallopian tubes, and an assessment of the pelvic lymph nodes (either by a mapping/sampling method or full removal)
- People whose surgery successfully removed all visible cancer, with no cancer found at the edges of the removed tissue and no remaining disease after the operation
- People whose cancer was confirmed as stage I or II (early stage) based on what was found during surgery, using the 2009 FIGO staging system
- People aged 18 years or older
- People who are able to begin radiation treatment within 12 weeks of their surgery date
Who may not be able to join:
- People who are currently receiving chemotherapy or hormonal therapy
- People who have had or currently have another cancer whose history or treatment could interfere with how the trial measures safety or effectiveness
- People who have previously had radiation therapy to the pelvic area
- People who have an active infection of the urinary or genital tract that requires antibiotics, unless it is a straightforward urinary tract infection
- People who have a history of active inflammatory bowel disease requiring treatment, such as Crohn's disease or ulcerative colitis
- People who have a psychiatric or medical condition that the trial investigator considers would make participation in the study unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kaled Alektiar, MD, Memorial Sloan Kettering Cancer Center
Phone: 212-639-7981
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
feasibility of B-mode ultrasound imaging
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.